Kornimate/medical-research-clean huggingface dataset:
resident observed burnout after daily supplementation with coffee

Conditions: Burnout, Professional

Summary: coffee drinking is frequently reported as a negative outcome in studies on burnout, but the effect of an increased coffee intake on resident burnout has not been reported in the literature. this study is a prospective, interventional cohort study enrolling up to 50 residents from the internal medicine residency program to look at the relationship between coffee and resident burnout.

resident burnout is increasingly being recognized as detrimental to both physician well being and patient care. it has been linked to an increased rate of medical errors and a reduced quality of patient care. in addition, there have been multiple high-profile physician suicides in the past years. this has resulted in a renewed focus on physician mental health and workload.

Eligibility criteria:
inclusion criteria: * a resident in the nyu internal medicine residency program exclusion criteria: * allergy or intolerance to coffee or caffeine * pregnancy
the role of mental imagery on approach motivation and behavioral engagement in social anxiety

Conditions: Social Anxiety; Social Phobia

Summary: efficacy of an online intervention aimed at enhancing both approach motivation and behavioral engagement in facing anxiety-provoking social situations among individuals with heightened social anxiety is investigated. upon receiving psychoeducation, participants will either undergo a prospective mental-imagery task or no additional task. the intervention's efficacy will be assessed by ratings of experienced and expected pleasure, approach motivation as well as self-reported engagement with feared situation one week later.

although exposure therapy is widely considered the gold standard for treating anxiety disorders, its effectiveness is often hindered by treatment discontinuation. many individuals avoid facing feared situations, yet exposure is crucial for successful extinction learning. therefore, there is a need for strategies to enhance both approach motivation and behavioral engagement in anxiety-provoking situations. within the depression literature, imagery-based interventions have already gained some support in increasing motivation and behavioral engagement in pleasurable activities through enhancement of reward anticipation as well as anticipatory and anticipated pleasure ('motivational amplifier' hypothesis). considering that social anxiety is characterized by disruptions in motivational and reward processes, prospective mental imagery may strengthen approach motivation and behavioral engagement in exposure to socially feared situations. thus, the present online study will investigate the effect of a prospective mental-imagery task on approach motivation and behavioral engagement in socially anxious individuals. following psychoeducation, participants in the experimental group will vividly imagine having successfully mastered the fear-provoking situation. the control group will receive only psychoeducation. approach motivation as well as reward anticipation, anticipated and anticipatory pleasure will be assessed before and after the psychoeducation and imagery task. engagement with the feared social situation will be assessed one week later. the aim of this randomized controlled trial in healthy individuals with heightened social anxiety is to investigate whether prospective mental imagery is effective in enhancing self-reported motivation and engagement with feared situation compared to a psychoeducation-only control group. in an exploratory analysis, we will investigate whether individuals' levels of reward sensitivity and anhedonia influence the effectiveness of prospective imagery training.

Eligibility criteria:
inclusion criteria: * elevated score on mini-social phobia inventory (mini-spin) \> 6 exclusion criteria: -
extraordinary measures for egyptian children with hemato-oncological disorders during covid-19 pandemic

Conditions: Coronavirus COVID-19

Summary: this is a prospective follow-up non-intervention study that will be carried out at hematology/ oncology department, children's hospital, ain-shams university, cairo, egypt. all followed-up children below 18 years with cancer during the one year study period from may 2020 till apr 2021 either at the out-patients clinic or inpatient department will be recruited.

study procedures: on admission or during the outpatient visit: 1. obtaining an informed consent . 2. full medical history, concurrent medications, demographic data and epidemiological data (history of contact to a covid-19 case, history of travel), will be obtained. 3. a thorough physical examination will be performed. 4. body weight, height, bmi, vital signs (blood pressure, heart rate and temperature) and blood oxygen saturation) will be recorded. 5. laboratory to perform the following tests: complete blood count with differential counts, covid -19 reverse transcription polymerase chain reaction (rt-pcr) test by nasopharyngeal swab. during admission: whenever unexplained fever and or respiratory symptoms developed or whenever covid19 suspected to have the following to be performed: 1. symptom developed that necessitates to repeat oropharyngeal and nasopharyngeal swab if indicated will be collected 2. chest x-ray or ct chest will be recorded. 3. laboratory to perform the following tests: complete blood count with differential counts, covid-19 rt-pcr test by oropharyngeal and nasopharyngeal swab: c-reactive protein and serum ferritin level. coagulation test; d. dimer, prothrombin time and inr. routine bacteriological study, blood culture and other symptoms/signs based cultures will be recorded on discharge: * date of discharge * period of admission * period of fever * a thorough physical examination will be performed * record the outcome

Eligibility criteria:
inclusion criteria: 1. children below 18 years with malignancy either hematological or solid tumors or 2. children below 18 years with hematological condition exclusion criteria: 1. patients or care-givers refusal to be enrolled in the study
computerized rotational head impulse test-vertical (crhit-vertical)

Conditions: Vestibular Function Tests

Summary: the purpose of this research study is to test whether a computerized rotational head impulse test-vertical (crhit-vertical) is able to reliably evaluate the vertical semicircular canals in patients with vestibular dysfunctions.


Eligibility criteria:
inclusion criteria: * subjects must be willing to tolerate the placement of a set of goggles on their face * controls: 1. no history of dizziness or imbalance 2. normal responses on rotational chair testing * patients: persons clinically diagnosed with vestibular disorders exclusion criteria: * pregnancy * neurodegenerative diseases

Keywords: vestibular neuritis vestibular migraine
a study to assess the change in disease activity in adult participants with moderate to severe ulcerative colitis treated with risankizumab compared to vedolizumab

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).this study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to severe uc who are naive to targeted therapies (tats). risankizumab and vedolizumab are approved medications for moderate to severe uc in multiple countries. participants who meet the eligibility criteria will be randomized in a 1:1 ratio to receive open label risankizumab or vedolizumab. approximately 530 adult participants with moderate to severe uc who are naïve to targeted therapies (tats) will be enrolled at 285 sites worldwide. for participants randomized to risankizumab, drug will be administered intravenous(iv) during the induction period followed by subcutaneous injection during the maintenance period. participants randomized to vedolizumab will receive drug iv throughout the study. the duration of the study is approximately 69 weeks for participants randomized to risankizumab and 71 weeks for participants randomized to vedolizumab. this includes up to a 35-day screening period followed by a treatment period of 44 weeks for risankizumab and 46 weeks for vedolizumab. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular outpatient visits during the study. the effect and safety of the treatment will be checked by medical assessments, evaluation of side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * participant has confirmed diagnosis of ulcerative colitis (uc) for at least 3 months prior to baseline. * participant has active uc with an modified mayo score (mms) of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central reader). * participant has demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates, oral locally acting steroids, systemic steroids (prednisone or equivalent), and immunomodulators. exclusion criteria: * participant has received any targeted therapies (tats) for uc, including but not limited to infliximab, etanercept, adalimumab, natalizumab, golimumab, ozanimod, ustekinumab, etrolizumab, vedolizumab, tofacitinib, filgotinib, etrasimod, guselkumab, mirikizumab, upadacitinib, and risankizumab. * participant with a current diagnosis of crohn's disease (cd) or irritable bowel disease (ibd)-unclassified or a history of radiation colitis or ischemic colitis. * currently known complications of uc such as: fulminant colitis and/or toxic megacolon, acute severe uc, previous colectomy (total or subtotal), or any other manifestation that might require surgery while in the study * active systemic infection/clinically important infection during the last 2 weeks prior to baseline visit as assessed by the investigator.
genotype-guided abbreviated dapt versus un-guided de-escalation therapy in patients with acs and hbr

Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI); High Bleeding Risk

Summary: the aim of this study is to assess the safety and efficacy of the cyp2c19 genotype-guided abbreviated dual antiplatelet therapy (dapt) strategy versus the un-guided stepwise intensity de-escalation of dapt strategy in patients with acute coronary syndrome (acs) and high bleeding risk (hbr) undergoing percutaneous coronary intervention (pci).

current guidelines recommend reducing the duration of dual antiplatelet therapy (abbreviated dapt) or de-escalating p2y12 inhibitor intensity (de-escalation therapy) in patients at risk of major bleeding, even in patients with acute coronary syndromes. a network meta-analysis that indirectly compared these two strategies found that abbreviated dual antiplatelet therapy reduced major bleeding compared with de-escalated dual antiplatelet therapy. unlike prasugrel and ticagrelor, which are potent p2y12 inhibitors, clopidogrel is activated in the liver via the cytochrome p450 2c19 (cyp2c19) metabolic pathway to exert its antiplatelet effects. its use as monotherapy requires caution, given that cyp2c19 genotypes that may be resistant to clopidogrel are more prevalent in asian populations than in western populations. therefore, this study aimed to compare the clinical outcomes and confirm the efficacy and safety of an abbreviated dual antiplatelet therapy (abbreviated dapt, p2y12 inhibitor monotherapy) strategy based on cyp2c19 genetic testing and a step-down dapt strategy (de-escalation therapy) after 1 month of maintenance potent p2y12 inhibitor-based dual antiplatelet therapy in patients at hbr who underwent pci for acs.

Eligibility criteria:
inclusion criteria: * patients must be at least 19 years of age * patients who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily. * patients presenting with acs (st-elevation myocardial infarction \[stemi\] or non-st-elevation \[nste\] acs). * patients with at least one lesion with equal or greater than 50% diameter stenosis requiring treatment with drug-eluting stents in native coronary artery or graft. * patients with high bleeding risk (by arc-hbr definition or precise-dapt score 25 or more) exclusion criteria: * patients unable to provide consent. * patients who need chronic anti-coagulation therapy. * patients suffering from cardiogenic shock or cardiac arrest * patients with known intolerance to aspirin, all p2y12 inhibitors, or components of drug-eluting stents. * clinically significant out of range values for platelet count (\< 50,000/mm3) or hemoglobin (\<8 g/dl) at screening * non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment). * pregnant or lactating women.

Keywords: cyp2c19 genotype acute coronary syndrome de-escalation therapy p2y12 inhibitor monotherapy high bleeding risk
theobromine from cocoa and cardiovascular risk factors

Conditions: Hypertension

Summary: the goal of this clinical trial is to examine whether consumption of dark chocolate affects blood pressure and a cardiovascular risk factor called trimethylamine n-oxide in thai male participants with hypertension. the main questions it aims to answer are: can consumption of dark chocolate lower blood pressure? can consumption of dark chocolate lower blood trimethylamine n-oxide? researchers will compare dark chocolate to white chocolate to see if the effects are due to theobromine (a key bioactive compound in dark chocolate). participants will consume either 100 g 72% dark chocolate bar or 80 g white chocolate bar daily for 14 days, rest for 7 days, and then switch to the other type of chocolate.

this is a randomized cross-over trial conducted in chiang mai, thailand. the goal of this clinical trial is to examine whether consumption of dark chocolate affects cardiovascular risk factors, with the primary outcomes being blood pressure and a cardiovascular risk factor called trimethylamine n-oxide. participants are thai males aged 35-70 years with hypertension who live in the chiang mai area. 42 participants will consume either 100 g 72% dark chocolate bar (\~2.5 servings, providing \~900 mg theobromine) or 80 g white chocolate bar (\~2 servings, providing 0 mg theobromine) daily for 14 days. after a 7-day wash-out period, the participant will repeat the protocol with the other intervention.

Eligibility criteria:
inclusion criteria * male * age between 35 to 70 years * bmi less than 30 kg/m\^2 * systolic blood pressure between 130 to 159 mmhg or diastolic blood pressure between 85 to 99 mmhg. * do not smoke. exclusion criteria * cannot drink beverages and consume foods that have caffeine. * take medicine to lower cholesterol and triglyceride levels, treat high blood pressure, or diabetes. * have liver and kidney inflammation. * use antibiotics within 1 month of study. * use choline or probiotic supplements regularly within 1 month of study. * consume more than 30 alcoholic drinks per week. * have chronic diseases.

Keywords: cocoa consumption theobromine trimethylamine-n-oxide crossover randomized trial chocolate consumption
topically applied idp-118 lotion and hp monad lotion in subjects with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: suppression potential of topically applied idp-118 lotion and hp monad lotion in subjects with moderate to severe plaque psoriasis.

a phase 1b open-label, randomized study evaluating the absorption and systemic pharmacokinetics and hpa axis suppression potential of topically applied idp-118 lotion and hp monad lotion in subjects with moderate to severe plaque psoriasis.

Eligibility criteria:
inclusion criteria: * male or female of any race, at least 18 years old of age (inclusive) * freely provides both written and oral informed consent. * has a clinical diagnosis of psoriasis at the baseline visit with an investigator's global assessment score of 3 or 4. the face, scalp ,axillae, and intertriginous areas are to be excluded in this calculation. * has an area of plaque psoriasis for topical treatment that involves a bsa of at least 20%. * the willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study. key exclusion criteria: * has spontaneously improving or rapidly deteriorating plaque psoriasis or postural psoriasis, as determined by the investigator. * presents with psoriasis that was treated with prescription medication and failed to respond to presents). * has a history of adrenal disease. * presents with any other concurrent skin conditions that could interfere with the evaluation of the treatment areas, as determined by the investigator. * is pregnant, nursing, or planning pregnancy during the study period.
outcome after descemet membrane endothelial keratoplasty (dmek) and ultra-thin descemet stripping automated endothelial keratoplasty (dsaek)

Conditions: Fuchs' Endothelial Corneal Dystrophy; Bullous Keratopathy; Iridocorneal Endothelial Syndrome; Posterior Polymorphous Dystrophy; Endothelial Dysfunction

Summary: the purpose of this study is evaluate the outcome after posterior lamellar keratoplasty (dmek and ultra-thin dsaek) for corneal transplantation.


Eligibility criteria:
inclusion criteria: * male or female aged 18 or older * scheduled to undergo endothelial keratoplasty * able to provide written informed consent. exclusion criteria: * age less than 18 years
long-term pas in rehabilitation after sci

Conditions: Spinal Cord Injuries

Summary: the investigators have recently shown in two pilot incomplete sci patients that long-term paired associative stimulation is capable of restoring voluntary control over some paralyzed muscles and enhancing motor output in the weak muscles (1). in this study, the investigators will administer long-term paired associative stimulation to incomplete sci patients in a long-term manner, keeping each patient in the study for as long as continuous improvement is observed.


Eligibility criteria:
inclusion criteria: * incomplete sci exclusion criteria: * epilepsy * metal inclusion in the head area * pacemaker * hearing device * high intracranial pressure
study to evaluate the safety and pharmacokinetics of ckd-331

Conditions: Hypertension and Dyslipidemia

Summary: phase 1 study to evaluate the safety and pharmacokinetics of ckd-331 in healthy adult volunteers

an open-label, randomized, single-dose, 2-sequence, 4-period, cross-over, phase 1 study to evaluate the safety and pharmacokinetics of ckd-331 in healthy adult volunteers

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19 years 2. weight ≥55kg with calculated body mass index (bmi) of 18 to 30 kg/m2 3. those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 4. those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ecg results at screening. 5. those who agree to contraception during the participation of clinical trial. 6. individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. exclusion criteria: 1. those who have no medical history of digestive disease, cardiovascular disease, endocrine disease, respiratory system, blood·tumor disease, infection disease, nephrology disease, genitourinary disease, neuron disease, skeletal disease, immunological disease, otolaryngological disease, dermatological disease, ophiological disease 2. those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 3. those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month before the first administration of investigational products. 4. those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 5. those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month. 6. those who exceed an alcohol and cigarette consumption than below criteria alcohol * man: 21 glasses/week * woman: 14 glasses/week (1 glass: soju 50ml, wine 30ml, or beer 250ml) smoking: 20 cigarettes/day 7. those who have genetic problems such as galactose intolerance, lapp lactose deficiency or glucose-galactose malabsorption. 8. those who are deemed insufficient to participate in this clinical study by investigators. 9. woman who are pregnant or breastfeeding.
neurocognition after gamma knife radiosurgery for multiple brian metastases

Conditions: Neoplasm Metastases

Summary: cancer which spreads to the brain (brain metastases) is a common and significant problem. historically, whole-brain radiotherapy has been used to treat these patients but has a negative effect on cognition. radiosurgery is an alternative treatment with potential for fewer cognitive side effects. the impact of radiosurgery alone on the cognitive function of patients with multiple brain metastases is not well studied. we propose a pilot study at the winnipeg centre for gamma knife surgery to examine this issue.

patients with \>=4 brain metastases will undergo gamma knife radiosurgery to a dose of 15-20 gy, depending on the maximum tumour diameter and number of metastases. a number of neurocognitive, quality of life, and toxicity assessments will be performed at baseline and at 6 weeks post-radiosurgery, then at months 4, 6, 12, 18, and every 6 months thereafter.

Eligibility criteria:
inclusion criteria: * pathologically proven solid tumour malignancy * age \>= 18 years * karnofsky performance status \>= 70 * \>= 4 brain metastases, all eligible to be treated with radiosurgery * all brain metastases \<= 4.0 cm in any diameter * pre-treatment contrast enhanced mri brain \<= 42 days prior to enrollment * patient able to provide his/her own written informed consent exclusion criteria: * prior radiosurgery, whole brain radiotherapy, or cranial radiotherapy * previous surgical resection of brain metastasis (biopsy is allowed) * prior chemotherapy ≤ 7 days prior to enrollment * planned chemotherapy during radiosurgery * leukemia, lymphoma, germ-cell tumour, small-cell lung cancer diagnosis * brainstem metastasis * leptomeningeal metastases * contraindication to mr imaging with contrast * pregnant or nursing women

Keywords: neoplasm metastasis brain neoplasms radiosurgery cognition disorders cranial irradiation